Effect of Body Mass Index on the Dose of Intrathecal Hyperbaric Bupivacaine for Elective Cesarean Section
NCT ID: NCT00403663
Last Updated: 2009-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2006-10-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our hypothesis is that obese women require less intrathecal hyperbaric bupivacaine than do normal weight women to achieve satisfactory surgical anesthesia for elective Cesarean section.Two groups of patients will be studied separately. Patients with BMI greater than or equal to 30 will be included in the obese group, also denominated study group. Patients with BMI less than 25 will be included in the normal weight group, also denominated control group. BMI will be calculated based on the patient's pre-pregnancy weight. For each group, the up-down sequential allocation method based on the Narayana rule will be used to find the minimum effective dose of intrathecal hyperbaric bupivacaine 0.75% associated with opioids necessary for satisfactory outcome in 95% of the pregnant women undergoing cesarean section, i.e. ED95.
There are two possible outcomes in our study: a satisfactory outcome is defined if the sensory block reaches at least at T6 and the patient does not complain of any pain or discomfort that requires intraoperative supplemental drugs; an unsatisfactory outcome is defined if the sensory block reaches a level lower than T6 or the patient complains of pain or discomfort that requires intraoperative supplemental drugs. The decision whether or not the supplementation is required will be made exclusively by the patient, and not by the physician in charge.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bupivacaine 0.75% with fentanyl and morphine
the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal weight group: All pregnant women at term (over 37 weeks) scheduled for elective Cesarean section, with pre-pregnancy BMI less than 25.
Exclusion Criteria
* Patients with any absolute or relative contraindication for spinal/epidural anesthesia.
* Patients with BMI between 25 and 30.
* Patients with more than one fetus.
* Patients unable to communicate in English effectively.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose CA Carvalho, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Anesthesia and Pain Management, Mount Sinai Hospital, University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mount Sinai Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-0206-E
Identifier Type: -
Identifier Source: secondary_id
06-02
Identifier Type: -
Identifier Source: org_study_id